Business Context and Reporting Period
Company: Agios Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 12, 2026
Context: The filing serves as a Regulation FD disclosure to announce the issuance of a press release outlining anticipated 2026 milestones. These milestones are scheduled for discussion at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.
Key Financial Metrics
This Form 8-K does not contain financial statements, revenue figures, profit data, cash flow metrics, margins, debt levels, or liquidity ratios. The filing is strictly informational regarding upcoming corporate communications.
Material Changes
No material financial changes or operational updates are detailed within the text of this filing. The document solely references the existence of a press release and presentation slides (Exhibits 99.1 and 99.2) containing the specific milestone details.
Guidance, Outlook, and Risks
- Outlook: The Company has issued a press release detailing anticipated milestones for the 2026 fiscal year.
- Management Commentary: The specific content of the outlook is contained in the attached press release and conference presentation slides, which are incorporated by reference but not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
- Risks and Contingencies: No specific risks or contingencies are enumerated in the body of this 8-K filing.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated January 12, 2026) for the full text of the 2026 milestones.
- Review Exhibit 99.2 (Presentation Slides) for detailed data to be presented at the J.P. Morgan Healthcare Conference.
- Note that the information in Item 7.01 is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section.
- Verify the date of the upcoming conference presentation (January 14, 2026) for real-time updates.